AR061296A1 - Procedimiento para hacer n-hidroxi-3- [4-[ [ [2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida y materiales de partida para la misma - Google Patents

Procedimiento para hacer n-hidroxi-3- [4-[ [ [2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida y materiales de partida para la misma

Info

Publication number
AR061296A1
AR061296A1 ARP070102498A ARP070102498A AR061296A1 AR 061296 A1 AR061296 A1 AR 061296A1 AR P070102498 A ARP070102498 A AR P070102498A AR P070102498 A ARP070102498 A AR P070102498A AR 061296 A1 AR061296 A1 AR 061296A1
Authority
AR
Argentina
Prior art keywords
methyl
phenyl
propenamide
indol
ethyl
Prior art date
Application number
ARP070102498A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38832681&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR061296A1 publication Critical patent/AR061296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP070102498A 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3- [4-[ [ [2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida y materiales de partida para la misma AR061296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80452706P 2006-06-12 2006-06-12
US86787806P 2006-11-30 2006-11-30

Publications (1)

Publication Number Publication Date
AR061296A1 true AR061296A1 (es) 2008-08-20

Family

ID=38832681

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102498A AR061296A1 (es) 2006-06-12 2007-06-08 Procedimiento para hacer n-hidroxi-3- [4-[ [ [2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida y materiales de partida para la misma

Country Status (31)

Country Link
US (2) US20090306405A1 (OSRAM)
EP (2) EP2394991B1 (OSRAM)
JP (2) JP5431926B2 (OSRAM)
KR (2) KR101493530B1 (OSRAM)
CN (4) CN101466674A (OSRAM)
AR (1) AR061296A1 (OSRAM)
AU (1) AU2007257883B2 (OSRAM)
BR (1) BRPI0712847A2 (OSRAM)
CA (1) CA2653657C (OSRAM)
CL (2) CL2007001691A1 (OSRAM)
DK (1) DK2032533T3 (OSRAM)
EC (1) ECSP088978A (OSRAM)
ES (2) ES2553255T3 (OSRAM)
GT (1) GT200800282A (OSRAM)
HR (1) HRP20130798T1 (OSRAM)
IL (2) IL195211A (OSRAM)
IN (1) IN2015DN00910A (OSRAM)
JO (1) JO2900B1 (OSRAM)
MA (1) MA30513B1 (OSRAM)
MX (2) MX2008015898A (OSRAM)
MY (1) MY147576A (OSRAM)
NO (1) NO341870B1 (OSRAM)
NZ (1) NZ572707A (OSRAM)
PE (2) PE20120221A1 (OSRAM)
PL (1) PL2032533T3 (OSRAM)
PT (1) PT2032533E (OSRAM)
RU (1) RU2448090C2 (OSRAM)
TN (1) TNSN08507A1 (OSRAM)
TW (1) TWI395734B (OSRAM)
WO (1) WO2007146718A2 (OSRAM)
ZA (1) ZA200809490B (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000004075A1 (it) 2020-02-27 2021-08-27 Flamma Spa Processo per la preparazione di panobinostat

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB146260A (en) 1918-07-11 1921-08-11 Elektro Osmose Ag A process for preparing proteids charged with immune substances
GB8531612D0 (en) * 1985-12-23 1986-02-05 Beecham Wuelfing Gmbh & Co Kg Compounds
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2004517334A (ja) 2001-01-09 2004-06-10 ノバルティス アクチエンゲゼルシャフト 化合物のインビボ活性をスクリーニングする迅速な方法
AU2002351844B2 (en) 2001-11-06 2006-12-21 Novartis Ag Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
MY147013A (en) * 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Also Published As

Publication number Publication date
EP2032533B1 (en) 2013-04-03
JP5431926B2 (ja) 2014-03-05
NO20090137L (no) 2009-03-03
IL195211A (en) 2014-08-31
JP5809223B2 (ja) 2015-11-10
KR20090015969A (ko) 2009-02-12
CL2010000973A1 (es) 2011-07-01
JO2900B1 (en) 2015-09-15
EP2394991A1 (en) 2011-12-14
AU2007257883B2 (en) 2011-09-29
TNSN08507A1 (en) 2010-04-14
IL233836A (en) 2017-05-29
MY147576A (en) 2012-12-31
BRPI0712847A2 (pt) 2012-08-07
NO341870B1 (no) 2018-02-12
JP2009540008A (ja) 2009-11-19
JP2014058532A (ja) 2014-04-03
CN101466674A (zh) 2009-06-24
EP2032533A2 (en) 2009-03-11
US8536346B2 (en) 2013-09-17
US20090306405A1 (en) 2009-12-10
NZ572707A (en) 2011-12-22
CA2653657C (en) 2015-10-27
PE20120221A1 (es) 2012-03-21
ECSP088978A (es) 2009-01-30
KR101493530B1 (ko) 2015-02-13
IL233836A0 (en) 2014-09-30
PL2032533T3 (pl) 2013-08-30
MX366213B (es) 2019-07-01
CN103086944A (zh) 2013-05-08
CA2653657A1 (en) 2007-12-21
AU2007257883A1 (en) 2007-12-21
PT2032533E (pt) 2013-06-28
EP2032533B8 (en) 2013-12-11
RU2448090C2 (ru) 2012-04-20
MA30513B1 (fr) 2009-06-01
EP2394991B1 (en) 2015-09-23
IN2015DN00910A (OSRAM) 2015-07-10
TWI395734B (zh) 2013-05-11
ZA200809490B (en) 2009-10-28
CL2007001691A1 (es) 2008-05-16
CN102174008A (zh) 2011-09-07
GT200800282A (es) 2009-03-09
HRP20130798T1 (en) 2013-09-30
US20120010418A1 (en) 2012-01-12
MX2008015898A (es) 2009-01-12
WO2007146718A2 (en) 2007-12-21
KR20140117703A (ko) 2014-10-07
WO2007146718A3 (en) 2008-06-19
KR101540194B1 (ko) 2015-07-28
CN102167678B (zh) 2013-08-28
ES2553255T3 (es) 2015-12-07
TW200815345A (en) 2008-04-01
HK1162029A1 (en) 2012-08-17
HK1126759A1 (en) 2009-09-11
RU2008151726A (ru) 2010-07-20
CN102167678A (zh) 2011-08-31
PE20080851A1 (es) 2008-08-18
DK2032533T3 (da) 2013-07-01
ES2416286T3 (es) 2013-07-31
IL195211A0 (en) 2009-08-03

Similar Documents

Publication Publication Date Title
AR061298A1 (es) Sales de n-hidroxi -3- [4- [ [ [2- (2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2- propenamida.composciones farmaceuticas.
PE20080259A1 (es) Compuestos y metodos para modular fxr
CN1056683A (zh) 草酰氨基酸衍生物，其制备方法及其用作抑制脯氨酸羟化酶的药物
EA200800700A1 (ru) Новые сульфонилпирролы как ингибиторы гдац (гистондезацетилазы)
PE20140879A1 (es) Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
SG156687A1 (en) Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
WO2007084390A3 (en) Histone deacetylase inhibitors
CL2023000223A1 (es) Nuevos inhibidores selectivos de hdac6 basados en oxadiazol
BR112015023399A2 (pt) inibidores de hdac
PE20061426A1 (es) Derivados de indol como inhibidores de la fosfolipasa a2 citosolica
NO20090135L (no) Polymorfer av N-hydroksy-3-[4-[[[-(2-metyl-1H-indol-3-yl)etyl]amino]metyl]fenyl]2E-2-propenamid
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
ECSP088957A (es) Composición farmacéutica estable que contiene docetaxel y método para su fabricación
EA200800791A1 (ru) Сульфонилпирролгидрохлориды, как ингибиторы гистондезацетилазы
BRPI0509982A (pt) cepa isolada de escherichia coli, e, método para produzir um composto
DK1776358T3 (da) Substituerede propenylpiperazinderivater som nye inhibitorer af histondeacetylase
AR061296A1 (es) Procedimiento para hacer n-hidroxi-3- [4-[ [ [2- ( 2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2-propenamida y materiales de partida para la misma
ES2545076T3 (es) Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma
MX2021000468A (es) Inhibidores de la histona desacetilasa.
EA200701970A1 (ru) Гидроксаматы как ингибиторы гистондеацетилазы и содержащие их фармацевтические композиции
WO2004071401A3 (en) Hydroxamic acid derivatives as histone deacetylase inhibitors (hdca)
PE20091190A1 (es) Sales de adicion de inhibidores de la enzima de conversion de la angiotensina con acidos donadores de no, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
UY29268A1 (es) Sales farmaceuticamente aceptables de derivados de acido carboxilico
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου

Legal Events

Date Code Title Description
FB Suspension of granting procedure